Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Maxcyte (MXCT) EBIT Margin (2020 - 2026)

Maxcyte has reported EBIT Margin over the past 6 years, most recently at 656.3% for Q4 2025.

  • Quarterly EBIT Margin fell 99810.0% to 656.3% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 44.72% through Dec 2025, down 1861.0% year-over-year, with the annual reading at 44.72% for FY2025, 2250.0% down from the prior year.
  • EBIT Margin was 656.3% for Q4 2025 at Maxcyte, down from 207.19% in the prior quarter.
  • Over five years, EBIT Margin peaked at 341.8% in Q4 2024 and troughed at 656.3% in Q4 2025.
  • The 5-year median for EBIT Margin is 147.45% (2021), against an average of 163.97%.
  • Year-over-year, EBIT Margin soared 86807bps in 2024 and then tumbled -99810bps in 2025.
  • A 5-year view of EBIT Margin shows it stood at 425.03% in 2021, then skyrocketed by 93bps to 29.01% in 2022, then tumbled by -1714bps to 526.27% in 2023, then skyrocketed by 165bps to 341.8% in 2024, then tumbled by -292bps to 656.3% in 2025.
  • Per Business Quant, the three most recent readings for MXCT's EBIT Margin are 656.3% (Q4 2025), 207.19% (Q3 2025), and 167.24% (Q2 2025).